Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
r-HSA in Cirrhosis and Ascites
NCT05249374Phase 1Completed
- Sponsor
- Protogen
- Start
- Oct 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human serum albumin in Liver cirrhosis (LC) and ascites, sponsored by Protogen. Primary endpoints: Treatment-Emergent Adverse Events at 57 days and Serious Adverse Events at 57 days. Started Oct 2021; status: completed.
02
Drugs
recombinant human serum albumin
03
Conditions
Liver cirrhosis (LC)ascites
Beyond the preview
Go deeper on NCT05249374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249374.